Paper Details

  1. Home
  2. Paper Details

Current and Emerging Direct Oral Anticoagulants: State-of-the-Art.

Author: FavaloroEmmanuel J, GosselinRobert, LippiGiuseppe

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Direct oral anticoagulants (DOACs) are a new type of blood thinner that do not require regular monitoring. They have several advantages over older blood thinners, but further research is needed to understand their full effects.
Paper Details　
Original Abstract of the Article :
Anticoagulant drugs comprise a specific subcategory of antithrombotic agents that act to inhibit blood coagulation at various stages, reducing clot development and ultimately lowering the risk of developing new-onset or recurrent thrombosis. Although the long history of anticoagulant drugs has been ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1055/s-0039-1692703

データ提供：米国国立医学図書館（NLM）

The Rise of Direct Oral Anticoagulants

This article provides a comprehensive overview of the current and emerging landscape of [direct oral anticoagulants (DOACs)]. It discusses the mechanisms of action, efficacy, safety profiles, and clinical applications of various [DOACs], including [apixaban, dabigatran, edoxaban, rivaroxaban, betrixaban, darexaban, eribaxaban, letaxaban, nokxaban, AZD-0837, fidexaban, LY517717, odiparcil, otamixaban, TTP889, and ximelagatran]. The researchers emphasize the need for standardization in clinical trials and harmonization of drug licensing procedures to better understand the complex pharmacological profiles of these agents.

Revolutionizing Anticoagulation Therapy

This review highlights the transformative impact of [DOACs] on the field of [anticoagulation] therapy. These agents offer significant advantages over traditional anticoagulants, leading to improved patient outcomes and a shift towards more personalized treatment approaches.

Navigating the Anticoagulation Landscape

Healthcare professionals will find this review invaluable in navigating the diverse landscape of [anticoagulation] therapies. By providing a detailed overview of [DOACs], the article empowers clinicians to make informed decisions about treatment strategies for their patients.

Dr.Camel's Conclusion

This article examines the exciting advancements in [anticoagulation] therapy, focusing on the rise of [DOACs]. Like a camel crossing a desert landscape, this review guides us through the changing terrain of [anticoagulation], highlighting the remarkable progress and the challenges that lie ahead.

Date :
  1. Date Completed 2019-12-11
  2. Date Revised 2019-12-17
Further Info :

Pubmed ID

31216588

DOI: Digital Object Identifier

10.1055/s-0039-1692703

Related Literature

Article Analysis
・Side Effects of edoxaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.